CJC-1295: Complete Research Guide

At a Glance: The Short Version for Researchers

CJC-1295 is a 29-amino acid tetrasubstituted peptide analog of native growth hormone-releasing hormone (GHRH 1-29). In preclinical literature, it is primarily evaluated for its capacity to stimulate endogenous growth hormone (GH) synthesis and downstream insulin-like growth factor 1 (IGF-1) secretion without inducing significant prolactin or cortisol spikes.

The compound exists in two primary formulations: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (frequently referred to as Modified GRF 1-29). The DAC moiety covalently binds to circulating serum albumin, extending the peptide half-life from approximately 30 minutes to over 6 days in animal models.

When sourcing CJC-1295 for laboratory research, verifying lot-specific purity via high-performance liquid chromatography (HPLC) and mass spectrometry (MS) is critical. PX1 Research guarantees ≥99% purity and sub-0.05 EU/mg endotoxin thresholds across all CJC-1295 lots to ensure experimental reproducibility.

What Is CJC-1295 and How Does It Function?

CJC-1295 was originally developed to overcome the rapid enzymatic degradation characteristic of native GHRH. Endogenous GHRH is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) in blood plasma, resulting in an extremely short biological half-life of less than 10 minutes. CJC-1295 incorporates four specific amino acid substitutions (at positions 2, 8, 15, and 27) that shield the peptide chain against DPP-IV enzymatic cleavage.

By preserving structural integrity, CJC-1295 binds selectively to the GHRH receptor (GHRH-R) located on anterior pituitary somatotrophs. This receptor activation triggers adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This signal transduction cascade prompts both the synthesis and pulsatile release of endogenous growth hormone into systemic circulation.

In laboratory settings, researchers select CJC-1295 variants based on whether physiological GH pulsatility or sustained baseline GH elevation is required. To review individual analytical specifications or buy high-purity material, researchers can order 5 mg vials of CJC-1295 No DAC directly from our catalog.

CJC-1295 DAC vs. CJC-1295 No DAC (Mod GRF 1-29)

Understanding the biochemical distinction between CJC-1295 with DAC and CJC-1295 without DAC is crucial for designing accurate in vitro and animal models. While both peptides share identical amino acid substitutions in the core chain, the presence of the Drug Affinity Complex fundamentally alters pharmacokinetics.

CJC-1295 DAC includes a reactive maleimido derivative attached to the C-terminus of the peptide. Upon introduction to biological fluids, this maleimide group forms a dynamic, covalent bond with the free thiol group on serum albumin (Cys34). Because albumin has a long circulatory half-life, the conjugated CJC-1295 molecule escapes renal clearance and enzymatic degradation, resulting in a extended half-life of 6 to 8 days in preclinical models.

In contrast, CJC-1295 No DAC (Modified GRF 1-29) lacks the reactive affinity complex. It exhibits a rapid distribution phase and a half-life of approximately 30 minutes. This short half-life makes Mod GRF 1-29 ideal for research designs attempting to mimic natural physiological GH pulses. Laboratories requiring long-acting receptor saturation frequently order CJC-1295 DAC 2 mg to conduct extended time-course evaluations.

Preclinical Research: GH Pulsatility and IGF-1 Expression

Growth hormone-releasing peptides are extensively investigated for their downstream metabolic and regenerative signaling pathways. Preclinical trials demonstrate that CJC-1295 administration correlates with sustained increases in plasma growth hormone and a corresponding dose-dependent rise in liver-derived IGF-1.

IGF-1 acts as the principal mediator of growth hormone activity in peripheral tissues. Research models demonstrate that elevated IGF-1 concentrations enhance satellite cell proliferation, promote nitrogen retention, stimulate protein synthesis in skeletal muscle tissue, and accelerate connective tissue repair following mechanical strain.

Furthermore, CJC-1295 models show minimal disruption to secondary endocrine axes. Unlike non-selective secretagogues, CJC-1295 does not significantly alter systemic thyroid-stimulating hormone (TSH), prolactin, or cortisol levels. Researchers exploring targeted growth factor expression often compare CJC-1295 against other growth hormone releasing peptides to map distinct pathway kinetic profiles.

Experimental Protocols and Reconstitution Guidelines

All CJC-1295 products provided by PX1 Research arrive as lyophilized (freeze-dried) powders sealed under inert gas to maximize shelf stability. Lyophilized peptides should be stored in a climate-controlled environment at -20°C for short-term projects or -80°C for long-term storage, protected from direct light exposure.

Reconstitution must be performed under sterile laboratory conditions using sterile bacteriostatic water (0.9% benzyl alcohol). The solvent should be gently directed against the glass inner wall of the vial rather than sprayed directly onto the lyophilized peptide cake. Gentle swirl mixing is recommended; vortexing or vigorous agitation can disrupt secondary peptide structure and cause irreversible denaturation.

Post-reconstitution, CJC-1295 solution should be maintained at 2°C to 8°C and utilized within 21 to 30 days. To ensure reliable concentrations across repeated sampling, researchers should reference our detailed handling protocols in the PX1 Research Library before initiating laboratory procedures.

Comparing Peptide Quality: Analytical Verification Metrics

When evaluating CJC-1295 vendors, rigorous empirical data must supersede commercial marketing claims. Below is a detailed breakdown of the structural verification metrics that characterize research-grade CJC-1295:

Purity Verification: HPLC purity must exceed 99.0%, with clear resolution of minor synthesis byproducts and no single impurity exceeding 0.5% area under the curve.

Identity Confirmation: High-resolution Mass Spectrometry (ESI-MS or MALDI-TOF) must accurately confirm the molecular weight (3,367.97 Da for CJC-1295 No DAC; 3,647.28 Da for CJC-1295 DAC) within a 1 Da tolerance.

Endotoxin Levels: Limulus Amebocyte Lysate (LAL) testing must verify bacterial endotoxins remain below 0.05 EU/mg to prevent inflammatory confounding in cell culture or animal assays.

Lot Traceability: Every vial must be tied to a distinct batch number with an independently accessible, lot-matched Certificate of Analysis (COA).

Sourcing and Synthesis: Solid-Phase Peptide Synthesis (SPPS) performed in USA-controlled facilities ensures reproducible sequence fidelity and total removal of residual trifluoroacetic acid (TFA) salts.

Shipping and Logistics: Lyophilized peptides must be dispatched quickly via temperature-monitored domestic fulfillment centers to avoid prolonged exposure to elevated ambient heat.

Red Flags: How to Vet a CJC-1295 Supplier

Selecting a supplier based solely on surface-level cost introduces significant risk to empirical validity. Low-tier vendors frequently distribute unrefined or mislabeled peptides that contain toxic heavy metals, residual synthesis reagents, or mismatched peptide sequences.

A major red flag is a supplier that provides a 'generic' or non-downloadable COA that lacks a specific lot number, date, or mass spectrum printout. Vendors relying on static, years-old analytical documents often re-use single test reports across multiple unverified batches imported from overseas re-packagers.

Another critical vulnerability is the complete omission of endotoxin testing. Endotoxins (lipopolysaccharides) alter cell viability and stimulate non-specific cytokine release in research models, invalidating physiological measurements. If a vendor cannot produce lot-specific LAL assay results demonstrating sub-0.05 EU/mg contamination, the material is unfit for controlled scientific experimentation.

Synergistic Research Clusters: Combining GHRH and GHRP Compounds

In neuroendocrine research, combining a GHRH analog with a Ghrelin/Growth Hormone Secretagogue Receptor (GHSR) agonist produces a profound synergistic effect on pituitary growth hormone release. While GHRH increases the amplitude of GH secretion, GHRPs inhibit somatostatin tone and enhance signal transduction.

Preclinical designs frequently evaluate CJC-1295 No DAC alongside selective GHRPs like Ipamorelin. Co-administration of these two compounds results in a far greater GH release than the additive sum of either peptide administered independently, without triggering hypercortisolemia.

Laboratories investigating dual-pathway secretagogue kinetics can explore Ipamorelin research peptides alongside CJC-1295, or browse our complete catalog of research peptides to establish customized receptor co-activation protocols.

Ordering CJC-1295 from PX1 Research

PX1 Research provides standardized 2 mg, 5 mg, and 10 mg lyophilized vials of CJC-1295 (DAC and No DAC formulations) synthesized under stringent USA laboratory quality controls. Each shipment includes vacuum-sealed, tamper-evident vials ready for immediate reconstitution.

All orders placed before 3:00 PM EST Monday through Friday ship same-day from our strategically situated distribution hubs in California and Arizona. Fast, fully tracked domestic transit minimizes ambient thermal transit times, ensuring structural peptide stability upon delivery.

Every single batch of CJC-1295 sold is accompanied by a downloadable, lot-matched COA reflecting independent HPLC, MS, and endotoxin analysis. For large-scale studies or institution-wide purchasing, visit our portal for wholesale bulk research peptides or secure your inventory directly through our verified product page today.